The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBA
CureMetrix
Mammography artificial intelligence software designed to detect breast anomalies early.
What they do
The company develops artificial intelligence software designed for mammography and breast imaging. Its algorithms analyze screening mammograms to detect and classify breast anomalies, such as calcifications and masses, helping radiologists improve diagnostic sensitivity, reduce false positives, and identify early signs of breast cancer.
The record
- Vertical
- Diagnostics & Imaging
- Sub-segment
- AI oncology diagnostics
- Product type
- Software as a medical device
- Stage
- Series A
- Headquarters
- San Diego, United States
- Region
- North America
- Founded
- 2013
- Total funding
- $15M raised
Notable investors: Kemper-Saban Ventures, SpringTide, Trilogy.
Also in Diagnostics & Imaging
Related on The Signal
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
Liquid biopsy monitoring is turning precision oncology into a continuous process, not a one time test
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA